Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation - PubMed (original) (raw)
Review
Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation
Lara M Myers et al. Trends Immunol. 2005 Aug.
Abstract
Historically, co-stimulation has been regarded as a prerequisite for T-cell activation. A lack of co-stimulation results in peripheral T-cell tolerance, which manifests as unresponsiveness or death through apoptosis. Recent findings, however, suggest that eliciting co-stimulation can also induce tolerance. Reconciling these diametrically opposed results is certainly of academic importance but more importantly transcends basic immunology and impacts present and future clinical trials that are centered on modulating T-cell co-stimulation. This review will focus on CD137 (4-1BB) and propose a mechanism of action in which CD137-primed CD8 T cells express effector function and also inhibit CD4 T-cell activation. This model suggests that the same CD8 T cells possess antitumor effector function interfaced with regulatory capacity, which ultimately leads to concomitant inhibition of tumorigenesis and autoimmune disease.
Similar articles
- Immunotherapy with agonistic anti-CD137: two sides of a coin.
Sun Y, Chen JH, Fu Y. Sun Y, et al. Cell Mol Immunol. 2004 Feb;1(1):31-6. Cell Mol Immunol. 2004. PMID: 16212918 Review. - Involvement of 4-1BB (CD137)-4-1BBligand interaction in the modulation of CD4 T cell-mediated inflammatory colitis.
Maerten P, Kwon BS, Shen C, De Hertogh G, Cadot P, Bullens DM, Overbergh L, Mathieu C, Van Assche G, Geboes K, Rutgeerts P, Ceuppens JL. Maerten P, et al. Clin Exp Immunol. 2006 Feb;143(2):228-36. doi: 10.1111/j.1365-2249.2005.02991.x. Clin Exp Immunol. 2006. PMID: 16412046 Free PMC article. - Role of 4-1BB in immune responses.
Vinay DS, Kwon BS. Vinay DS, et al. Semin Immunol. 1998 Dec;10(6):481-9. doi: 10.1006/smim.1998.0157. Semin Immunol. 1998. PMID: 9826581 Review. - Therapeutic potential of 4-1BB (CD137) as a regulator for effector CD8(+) T cells.
Kim YJ, Broxmeyer HE. Kim YJ, et al. J Hematother Stem Cell Res. 2001 Aug;10(4):441-9. doi: 10.1089/15258160152509064. J Hematother Stem Cell Res. 2001. PMID: 11522228 Review. - Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, Shu S. Kim JA, et al. Cancer Res. 2001 Mar 1;61(5):2031-7. Cancer Res. 2001. PMID: 11280763
Cited by
- Signaling by Fyn-ADAP via the Carma1-Bcl-10-MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells.
Rajasekaran K, Kumar P, Schuldt KM, Peterson EJ, Vanhaesebroeck B, Dixit V, Thakar MS, Malarkannan S. Rajasekaran K, et al. Nat Immunol. 2013 Nov;14(11):1127-36. doi: 10.1038/ni.2708. Epub 2013 Sep 15. Nat Immunol. 2013. PMID: 24036998 Free PMC article. - IFN-gamma-indoleamine-2,3 dioxygenase acts as a major suppressive factor in 4-1BB-mediated immune suppression in vivo.
Kim YH, Choi BK, Kang WJ, Kim KH, Kang SW, Mellor AL, Munn DH, Kwon BS. Kim YH, et al. J Leukoc Biol. 2009 May;85(5):817-25. doi: 10.1189/jlb.0408246. Epub 2009 Feb 13. J Leukoc Biol. 2009. PMID: 19218483 Free PMC article. - S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity.
Zhang J, Song K, Wang J, Li Y, Liu S, Dai C, Chen L, Wang S, Qin Z. Zhang J, et al. Oncoimmunology. 2018 Jan 23;7(4):e1296996. doi: 10.1080/2162402X.2017.1296996. eCollection 2018. Oncoimmunology. 2018. PMID: 29632708 Free PMC article. - Interleukin-6 induces Gr-1+CD11b+ myeloid cells to suppress CD8+ T cell-mediated liver injury in mice.
Cheng L, Wang J, Li X, Xing Q, Du P, Su L, Wang S. Cheng L, et al. PLoS One. 2011 Mar 4;6(3):e17631. doi: 10.1371/journal.pone.0017631. PLoS One. 2011. PMID: 21394214 Free PMC article. - Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation.
Adler AJ, Vella AT. Adler AJ, et al. Oncoimmunology. 2013 Jan 1;2(1):e22837. doi: 10.4161/onci.22837. Oncoimmunology. 2013. PMID: 23482891 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- AI 52108/AI/NIAID NIH HHS/United States
- R01 AI052108-01A1/AI/NIAID NIH HHS/United States
- R01 AI052108-03/AI/NIAID NIH HHS/United States
- R01 AI052108-05/AI/NIAID NIH HHS/United States
- T32 AI 07080/AI/NIAID NIH HHS/United States
- R01 AI052108-04/AI/NIAID NIH HHS/United States
- R01 AI052108/AI/NIAID NIH HHS/United States
- R01 AI052108-02/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials